Phase Genomics
Phase Genomics is a life science innovation company that develops ultra-long-range genome sequencing technology and computational tools for genomics, cytogenetics, oncology, and microbiology. The company's proprietary Proximo Hi-C and ProxiMeta platforms use proximity ligation to measure the physical proximity of DNA in vivo, enabling scientists to scaffold contigs into entire chromosomes, deconvolute complex…
Funding snapshot
About
Phase Genomics is a life science innovation company that develops ultra-long-range genome sequencing technology and computational tools for genomics, cytogenetics, oncology, and microbiology. The company's proprietary Proximo Hi-C and ProxiMeta platforms use proximity ligation to measure the physical proximity of DNA in vivo, enabling scientists to scaffold contigs into entire chromosomes, deconvolute complex metagenomic samples, reconstruct viral genomes, attribute mobile genetic elements to their hosts, and construct high-quality chromosome-scale reference genomes. These capabilities address critical challenges in cancer research, infectious disease surveillance, antibiotic resistance tracking, and plant and animal genomics. Founded in 2015 and headquartered in Seattle, Washington, Phase Genomics has raised approximately $5.8 million in Series A funding from investors including NHGRI, NIH, NIAID, the Gates Foundation, Congruent Ventures, Washington Research Foundation, and the National Cancer Institute.
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Delivery,
Life Sciences Platforms and Tools > Research Services > Genomics > Next Generation Sequencing (NGS)
Team background
Company Wise > Microsoft,
College Wise > Massachusetts Institute of Technology, Cornell University
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.